Caris Life Sciences Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its leadership in precision oncology, molecular diagnostics, and oncology bioinformatics. The company detailed its expanding offerings in early detection, minimal residual disease (MRD), and monitoring, as well as its technology-enabled platform supporting more than 6,000 oncologists in the U.S. Caris also reported continued growth in its Precision Oncology Alliance (POA), now comprising 99 member sites—including 46 NCI-designated cancer centers—and providing access to a clinico-genomic dataset of over 740,000 patients. The company supports research, publication, and clinical trial efforts across more than 700 locations, with a network of over 4,000 oncologists. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.